Ventilatory Threshold and Risk of Pulmonary Exacerbations in Cystic Fibrosis

被引:0
|
作者
Campos, Natalia E. [1 ]
Vendrusculo, Fernanda M. [1 ]
Perez-Ruiz, Margarita [2 ]
Donadio, Marcio V. F. [1 ,3 ,4 ]
机构
[1] Pontificia Univ Catolica Rio Grande do Sul, Infant Ctr, Lab Pediat Phys Act, Porto Alegre, RS, Brazil
[2] Univ Politecn Madrid, Fac Ciencias Act Fis & Deporte, Dept Hlth & Human Performance, Madrid, Spain
[3] Univ Int Catalunya, Fac Med & Ciencias Salud, Dept Physiotherapy, Barcelona, Spain
[4] Ctr Infant, Lab Pediat Phys Act, Av Ipiranga 6690,2 Andar, BR-90610000 Porto Alegre, RS, Brazil
关键词
  cystic fibrosis; pulmonary exacerbation; anaerobic threshold; exercise capacity; prognosis; oxygen consumption; QUALITY-OF-LIFE; HEART-FAILURE; NUTRITIONAL-STATUS; PEAK VO2; CHILDREN; HOSPITALIZATION; STANDARDIZATION; ABNORMALITIES; SPIROMETRY; FREQUENCY;
D O I
10.4187/respcare.10428
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
BACKGROUND: Whereas pulmonary exacerbations and aerobic fitness play a key role in the prognosis of cystic fibrosis (CF), the use of ventilatory threshold data as markers of exacerbation risk has been scarcely addressed. This study sought to examine the association between aerobic fit-ness, assessed through ventilatory threshold variables recorded during cardiopulmonary exercise testing (CPET), and the risk of exacerbations in individuals with CF. METHODS: Participants of this retrospective cohort study were subjects from 6 y of age. Over a 4-y period, the following data were recorded: lung function indicators, CPET variables, time to first exacerbation and an-tibiotic use, along with demographic, clinical, and anthropometric data. RESULTS: The mean age of 20 subjects included was 16 +/- 5.4 y. Univariate regression analysis revealed that lung function (FEV1: Cox hazard ratio [HR] 0.97, P = .03; and forced expiratory flow between 25- 75% of vital capacity [FEF25-75]: Cox HR 0.98, P = .036) and aerobic fitness (oxygen consump-tion [VO2] at ventilatory threshold: Cox HR 0.94, P = .01; and ventilatory equivalent for carbon dioxide [VE/VCO2] at ventilatory threshold: Cox HR 1.13, P = .049) were associated with exacerba-tion risk, whereas in the multivariate model, only VO2 at the ventilatory threshold (%max) (Cox HR 0.92, P = .01) had a significant impact on this risk. Consistently, individuals experiencing exacerba-tion had significantly lower VO2 values (%max) at the ventilatory threshold (P = .050) and higher ventilatory equivalent for oxygen consumption (VE/VO2) (P = .040) and VE/VO2 (P = .037) values at the ventilatory threshold. Time to exacerbation was significantly correlated with VO2 at the ventila-tory threshold (r = 0.50, P = .02), VE/VO2 (r = -0.48, P = .02), and VE/VCO2 (r = -0.50, P = .02). CONCLUSIONS: Our results suggest an association between CPET variables at the ventila-tory threshold and exacerbations. Percentage VO2 at the ventilatory threshold could serve as a complementary variable to monitor exacerbations in people with CF.
引用
收藏
页码:620 / 627
页数:8
相关论文
共 50 条
  • [21] Changing thresholds and incidence of antibiotic treatment of cystic fibrosis pulmonary exacerbations, 1995-2005
    VanDevanter, Donald R.
    Elkin, Eric P.
    Pasta, David J.
    Morgan, Wayne J.
    Konstan, Michael W.
    JOURNAL OF CYSTIC FIBROSIS, 2013, 12 (04) : 332 - 337
  • [22] Cystic Fibrosis Pulmonary Guidelines Treatment of Pulmonary Exacerbations
    Flume, Patrick A.
    Mogayzel, Peter J., Jr.
    Robinson, Karen A.
    Goss, Christopher H.
    Rosenblatt, Randall L.
    Kuhn, Robert J.
    Marshall, Bruce C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 180 (09) : 802 - 808
  • [23] Lung clearance index predicts pulmonary exacerbations in young patients with cystic fibrosis
    Vermeulen, Francois
    Proesmans, Marijke
    Boon, Mieke
    Havermans, Trudy
    De Boeck, Kris
    THORAX, 2014, 69 (01) : 39 - 45
  • [24] Update on treatment of pulmonary exacerbations in cystic fibrosis
    Smyth, Alan
    CURRENT OPINION IN PULMONARY MEDICINE, 2006, 12 (06) : 440 - 444
  • [25] Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis
    Ryan, Gerard
    Jahnke, Nikki
    Remmington, Tracey
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (12):
  • [26] The role of inflammation in cystic fibrosis pulmonary exacerbations
    Houston, Claire J.
    Taggart, Clifford C.
    Downey, Damian G.
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2020, 14 (09) : 889 - 903
  • [27] Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis
    Smith, Sherie
    Rowbotham, Nicola J.
    Charbek, Edward
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2022, (08):
  • [28] Special considerations for the treatment of pulmonary exacerbations in children with cystic fibrosis
    Waters, Valerie
    Stanojevic, Sanja
    Ratjen, Felix
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2016, 10 (11) : 1221 - 1228
  • [29] Effect of Treatment of Cystic Fibrosis Pulmonary Exacerbations on Systemic Inflammation
    Sagel, Scott D.
    Thompson, Valeria
    Chmiel, James F.
    Montgomery, Gregory S.
    Nasr, Samya Z.
    Perkett, Elizabeth
    Saavedra, Milene T.
    Slovis, Bonnie
    Anthony, Margaret M.
    Emmett, Peggy
    Heltshe, Sonya L.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2015, 12 (05) : 708 - 717
  • [30] BEAT CF pulmonary exacerbations core protocol for evaluating the management of pulmonary exacerbations in people with cystic fibrosis
    Schultz, Andre
    McLeod, Charlie
    Berry, Scott
    Marsh, Julie
    McKenzie, Anne
    Messer, Mitch
    Wood, Jamie
    Saville, Ben
    Jaffe, Adam
    Ranganathan, Sarath
    Stick, Steve
    Wark, Peter
    Webb, Steve
    Snelling, Tom
    TRIALS, 2023, 24 (01)